Company Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders.
It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Efineptakin alfa, a recombinant human IL-7 that is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial.
Its product candidates also includes TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; Givastomig, a tumor-dependent T cell engager for gastric and other cancers; TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for PD(L)-1 resistant tumors; and TJ-C64B, a bispecific antibody for ovarian and other cancers.
The company has strategic collaboration agreement with PT Kalbe Genexine Biologics; AbbVie Ireland Unlimited Company; Jumpcan Pharmaceutical Group; Sinopharm Group Co. Ltd.; and Roche Diagnostics.
I-Mab was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.
| Country | China |
| Founded | 2014 |
| IPO Date | Jan 17, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 378 |
| CEO | Raj Kannan |
Contact Details
Address: Suite 400, 2440 Research Blvd Rockville, Maryland 20850 United States | |
| Phone | (301) 670 2800 |
| Website | i-mabbiopharma.com |
Stock Details
| Ticker Symbol | IMAB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $14.00 |
| CIK Code | 0001778016 |
| CUSIP Number | 44975P103 |
| ISIN Number | US44975P1030 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Raj Kannan | Chief Executive Officer and Director |
| Dr. Jerry Wang | Co-Founder and Chief Scientific Officer |
| Skelton Joseph | Chief Financial Officer |
| Tianyi Zhang | Vice President of Investor Relations |
| Dr. Fernando J. Salle´s Ph.D. | Senior Vice President and Head of U.S. and EU Business Development |
| Claire Xu | Head of US site |
| Dr. John Hayslip M.D. | Chief Medical Officer |
| Min Yin | Senior Vice President of Operations |
| Tyler Ehler | Senior Director of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 15, 2024 | 6-K | Report of foreign issuer |
| Apr 2, 2024 | 6-K | Report of foreign issuer |
| Apr 1, 2024 | 6-K | Report of foreign issuer |
| Mar 15, 2024 | 144 | Filing |
| Mar 15, 2024 | 6-K | Report of foreign issuer |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 9, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 8, 2024 | 144 | Filing |
| Feb 7, 2024 | 6-K | Report of foreign issuer |
| Feb 6, 2024 | SCHEDULE 13G | Filing |